NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/transmedics-group-inc. Investors have until April 15, 2025, to ask the Court to b ...

TransMedics Group (TMDX 0.09%) once ranked among the hottest healthcare stocks around. Shares of the medical technology company delivered a gain of more than ninefold between the beginning of 2022 and late August of 2024.However, TransMedics has become a dumpster fire for investors since then. The stock plunged roughly 60%. But such sell-offs can sometimes present great opportunities for forward-thinking investors. Could TransMedics Group stock be a millionaire-maker in the making?Many of the right ingredie ...

NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of TransMedics investors who were adversely affected by alleged securities fraud between February 28, 2023 and January 10, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/transmed ...

NEW YORK, March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of TransMedics Group, Inc. (NASDAQ: TMDX).Shareholders who purchased shares of TMDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/transmedics-group-inc-loss-submission-form-2/?id=138822&from=4CLASS PERIOD: Febr ...

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of those who acquired TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ:TMDX) securities during the period from February 28, 2023, through January 10, 2025 (“the Class Period”). Investors have until April 15, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsui ...

SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons or entities who purchased or otherwise acquired TransMedics Group, Inc. (NASDAQ: TMDX) securities between February 28, 2023 and January 10, 2025. TransMedics describes itself as a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. For more information, submit a form, email atto ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In TransMedics To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in TransMedics between February 23, 2023 and January 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 26, 2 ...

Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, Inc. for alleged misconduct during the Class Period from February 28, 2023, to January 10, 2025 [1] Allegations Against TransMedics - The complaint alleges that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [3] - It is claimed that the company engaged in unsafe practices, concealed safety issues, and lacked proper safety oversight [3] - These actions purportedly exposed TransMedics to increased scrutiny and regulatory risks [3] Lead Plaintiff Process - Investors in TransMedics have until April 15, 2025, to seek appointment as a lead plaintiff representative through Kessler Topaz Meltzer & Check, LLP or other counsel [4] - A lead plaintiff acts on behalf of all class members and is typically the investor or small group with the largest financial interest [4] - The decision to serve as a lead plaintiff does not affect the ability to share in any recovery [4]

Core Viewpoint - TransMedics Group, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims of misconduct including fraudulent practices and safety issues [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Jewik v. TransMedics Group, Inc., and covers purchasers of TransMedics securities from February 28, 2023, to January 10, 2025 [1]. - Allegations include the use of kickbacks, fraudulent overbilling, and coercive tactics to generate revenue, as well as unsafe practices and lack of safety oversight [3]. - The lawsuit cites specific incidents, including a letter from U.S. Representative Paul Gosar accusing TransMedics of misconduct, which led to a decline in stock price [4]. Group 2: Impact on Stock Price - Following the allegations made by Scorpion Capital on January 10, 2025, regarding overbilling and providing rejected organs, TransMedics' stock price fell further [5]. Group 3: Legal Process - Investors who purchased TransMedics securities during the class period can seek appointment as lead plaintiff, representing the interests of the class [6]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [6]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud cases, having recovered $6.6 billion for investors in class action cases [7]. - The firm has been recognized for securing the most monetary relief for investors and has a significant history of large recoveries in securities class action lawsuits [7].

SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- A class-action lawsuit has been filed against the medical technology company, which specializes in organ transplant therapy, alleging that the company and certain executives engaged in fraudulent practices and concealed safety issues. The suit, captioned Jewik v. TransMedics Group, Inc., No. 25-cv-10385 (D. Mass.), represents investors who purchased or acquired TransMedics Group, Inc. (NASDAQ: TMDX) securities between February 28, 2023, and January 10, 2025. ...